Jay Bradner, M.D.

Learned today of the passing of Phil Low, a drug hunter, scholar, educator and just lovely man. His work to target cancer cells via folic acid receptors, among so many other creative ideas, were a source of inspiration so many years ago. It was an honor to work with him on PSMA radioligand therapy, and to develop his inventions further to real medicines while at Novartis. Phil was a dynamo in his Purdue laboratory, surrounded by adoring trainees, at a whiteboard or pounding through 80 packed Powerpoint slides in 30 breathless minutes. I am glad and better to have known you, Phil. Your memory is a blessing. linkedin.com/posts/purdue-u…

Happy Birthday, Ty! Good boy. Have some cheese.

Mitochondria and Chloroplasts set aside their differences (cellular respiration vs photosynthesis, oxygen vs light, christae vs thylakoids) @GordonConf this July. @VamsiMootha accepting abstracts and terminal electrons now.

@ideapharma Congratulations on a legacy of ideas, influence and impact. After a well deserved guitar solo, do continue to inspire on this and other channels. We are all tuned in.

After 25 of the best possible years, today was my last day at IDEA Pharma I wish my friends there, the best team I have ever worked with, the greatest success as they continue to change the industry for the better. I'll always be the company's biggest fan. I hope I've made some difference to one of the most important industries, and I don't think I'm done yet. I'm going to take some time with Clare, finish a couple of books that I have in draft, and remind myself why I have so many guitars… Thank you to everyone at IDEA. You've surrounded me with the biggest hearts and brains for a long time, and I've loved almost every minute. To Alexander Gray in particular, my smarter and better half, thank you for everything 🙏🏻

Had the pleasure of joining fellow biotech leaders at the #LongwoodHealthcareLeaders #SanFranciscoCEO meeting for a candid discussion on where R&D is headed — and how our industry must continue to evolve to meet unmet patient needs and deliver meaningful innovation. Thank you to @LongwoodLeaders and @LongwoodFund for convening such a thoughtful group and for the opportunity to share how @Amgen is designing the medicines of tomorrow.

@rosslevinemd Thank you Ross @rosslevinemd. Your work has discovered so many actionable targets in myeloid malignancies. AML quite urgently needs more therapeutic development. Proud to work alongside the Dark Blue innovators!

Thanks Bruce @LifeSciVC. Time cannot move fast enough to bring this brave idea and prototype medicine to patients with AML. As a stem cell transplant physician, I am well calibrated to the challenge AML patients face. All learnings, insights and leaders at @Amgen in ALL will be accessible to this amazing team of innovators.

Stunning use of dTAG to study rapid dynamics of chromatin structure and cis-regulatory interactions at high resolution. Blueprint for studying mechanistic effects of TF degraders / modulators.

@immasiddx @karpathy You have very nice handwriting.

Google’s Nano Banana Pro is by far the best image generation AI out there. I gave it a picture of a question and it solved it correctly in my actual handwriting. Students are going to love this. 😂

@skathire Thank you, Sek, so very pleased by these data and the warm reception. Onward!

PCSK9 inhibition (evolocumab) saves lives. 25% relative risk reduction (3-point MACE; coronary heart disease death, MI, ischemic stroke) 20% reduction in overall mortality!!! 12,257 patients, all without prior ASCVD event; 55% LDL-C reduction from median xxx to 45 mg/dl nejm.org/doi/full/10.10… Congratulations @jaybradner @Amgen

@LWahlster @bloodgenes That is a heavy-hitting table.

Star struck about meeting Dr. Hanna Mikkola, one of my science idols!

An inspired choice to lead a brilliant faculty of scholars. Congratulations, @mskcc CSO Ross Levine. I knew him when, and knew it then.

How to Succeed in Biotech. Part 2 of this thoughtful and insight-rich reflection by Bruce Booth @LifeSciVC, on the eve of his 20th Altas-versary. Plain spoken and approachable, a high yielding reaction. Great read whether working at a small biotech or the largest independent biotech in the world.

@Nicole_Paulk Wishing you an uncomplicated and steady recovery. Cancer messed with the wrong scientist!

CEO of cancer gene therapy company: gets cancer🤯 Double mastectomy: ✅ Irony level: off the charts 📈 Fuel: science, scars, spite — let’s FUCKING go🔥

Go Bears!!!

Honored to keynote at Nucleate Summit 2025 with 500 brilliant entrepreneurs & scientists. The energy was electric—proof the future of biotech is in very good hands. #MyCompany

From decoding the genome’s “dark matter” to designing next-gen medicines, @HowardYChang is the ideal leader for @Amgen Research. Tackling the toughest problems in therapeutic science requires deep insights into human biology, creative new technologies in molecular biology, comfort in computation, and a wiring for collaboration. Can think of nobody better to lead therapeutics discovery. Let's gooooo! #MyCompany Read more: nature.com/articles/d4157…

@annewoj23 Congratulations @annewoj23, cannot wait to see all your team contributes in this next chapter to our collective, and most importantly our individual, understanding of our humanity.

To the 23andMe Community, I am incredibly excited and humbled to share with you that TTAM Research Institute (TTAM), a new non—profit medical research organization that I founded and lead, has completed the acquisition of 23andMe.   I formed TTAM and pursued the acquisition of 23andMe because of my strong belief that everyone should continue to have the ability to learn about and benefit from their DNA, and that a non-profit structure is the best way to solidify our values and commitments to our customers, the scientific community and the world at large. Since its founding in 2006, 23andMe has stood for something revolutionary: that individuals should have a right to understand themselves at the most fundamental level — through their DNA.   Through their DNA they can understand their health risks , prevent disease and be true partners in participating in research that shapes the future of health and medicine. Understanding the code of life - our DNA - is one of the most exciting scientific missions of our lifetime.  Through our DNA, we can learn about our ancestry origins, prevent potential health issues, and help develop treatments that could benefit all of us.   Humans are 99.5% genetically identical, and we have DNA in common with everything alive today.  The pursuit to understand DNA will benefit all of us and all of life. That belief built one of the world’s most diverse and engaged genetic research communities. More than 15 million people have joined this journey, and over 80% have chosen to participate in research, contributing to over 275 peer-reviewed publications in cancer, cardiovascular disease, neurological disorders, and more.   These discoveries did not just stay academic - those discoveries were also translated into new genetic reports  for customers that helped them continue to learn about their own DNA.    Thank you to the 23andMe community that participated in research and contributed to discoveries that have had a meaningful impact for the world. I want to end on a personal note.   Over the last few years I unfortunately lost my father, my nephew and my sister.   These tragedies have sharpened my focus on what is most important to me and how I want to spend my time.   My passion is 23andMe.  The opportunity to give back to society with our research and help everyone benefit from learning about their genome with a healthier life, is a personal mission where I am dedicating my resources and my time.    We all have a disease or health condition that we care about .  By coming together as a single community, we are stronger and more powerful to make discoveries and to ultimately make a difference.   The future of healthcare belongs to all of us and it’s in our power to make a difference. I am honored to be back with 23andMe and look forward to sharing more with you in the weeks and years to come. With gratitude, Anne